Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registry

AIM: Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) and atrial fibrillation and patients previously treated with VKA are switched to NOAC therapy. Safety data for this switching are urgently ne...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Clin Pharmacol
Главные авторы: Beyer-Westendorf, Jan, Gelbricht, Vera, Förster, Kati, Ebertz, Franziska, Röllig, Denise, Schreier, Thomas, Tittl, Luise, Thieme, Christoph, Hänsel, Ulrike, Köhler, Christina, Werth, Sebastian, Kuhlisch, Eberhard, Stange, Thoralf, Röder, Ingolf, Weiss, Norbert
Формат: Artigo
Язык:Inglês
Опубликовано: BlackWell Publishing Ltd 2014
Предметы:
Drug Safety
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239984/
https://ncbi.nlm.nih.gov/pubmed/24697922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12391
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы